SHATTUCK LABS INC (STTK) Stock Price, Quote, News and Overview
NASDAQ:STTK - Nasdaq - US82024L1035 - Common Stock - Currency: USD
STTK Quote, Performance and Key Statistics
1.37
+0.08 (+6.2%)
The current stock price of STTK is 1.37 USD. In the past month the price increased by 18.1%. In the past year, price decreased by -85.19%.
STTK Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About STTK
Company Profile
Shattuck Labs, Inc. engages in the research and development of dual-sided fusion proteins used for medical treatment of cancer and autoimmune disease. The company is headquartered in Austin, Texas and currently employs 75 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. The company is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. The company has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. The company has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Company Info
SHATTUCK LABS INC
500 W. 5Th Street, Suite 100
Austin TEXAS 78703 US
CEO: Taylor Schreiber
Employees: 75
Company Website: https://www.shattucklabs.com/
Investor Relations: https://ir.shattucklabs.com/
Phone: 15129004690
SHATTUCK LABS INC / STTK FAQ
What is the stock price of SHATTUCK LABS INC today?
The current stock price of STTK is 1.37 USD. The price increased by 6.2% in the last trading session.
What is the ticker symbol for SHATTUCK LABS INC stock?
The exchange symbol of SHATTUCK LABS INC is STTK and it is listed on the Nasdaq exchange.
On which exchange is STTK stock listed?
STTK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SHATTUCK LABS INC stock?
11 analysts have analysed STTK and the average price target is 1.22 USD. This implies a price decrease of -10.66% is expected in the next year compared to the current price of 1.37. Check the SHATTUCK LABS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SHATTUCK LABS INC worth?
SHATTUCK LABS INC (STTK) has a market capitalization of 65.40M USD. This makes STTK a Micro Cap stock.
How many employees does SHATTUCK LABS INC have?
SHATTUCK LABS INC (STTK) currently has 75 employees.
What are the support and resistance levels for SHATTUCK LABS INC (STTK) stock?
SHATTUCK LABS INC (STTK) has a support level at 1.25 and a resistance level at 1.37. Check the full technical report for a detailed analysis of STTK support and resistance levels.
Is SHATTUCK LABS INC (STTK) expected to grow?
The Revenue of SHATTUCK LABS INC (STTK) is expected to grow by 494.61% in the next year. Check the estimates tab for more information on the STTK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SHATTUCK LABS INC (STTK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of STTK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of STTK, evaluating the profitability, health, valuation and growth aspects
- SHATTUCK LABS INC (STTK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SHATTUCK LABS INC (STTK) Sales and EPS estimates to see what analysts future expectations are.
- SHATTUCK LABS INC (STTK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SHATTUCK LABS INC (STTK) Insider and Institutional Ownership to learn about the owners and their transactions.
- SHATTUCK LABS INC (STTK) Stock Chart to make your own analysis
- SHATTUCK LABS INC (STTK) Latest news and press-releases to stay up to date.
Does SHATTUCK LABS INC (STTK) stock pay dividends?
STTK does not pay a dividend.
When does SHATTUCK LABS INC (STTK) report earnings?
SHATTUCK LABS INC (STTK) will report earnings on 2025-03-18, after the market close.
What is the Price/Earnings (PE) ratio of SHATTUCK LABS INC (STTK)?
SHATTUCK LABS INC (STTK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).
What is the Short Interest ratio of SHATTUCK LABS INC (STTK) stock?
The outstanding short interest for SHATTUCK LABS INC (STTK) is 4.73% of its float. Check the ownership tab for more information on the STTK short interest.
STTK Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to STTK. When comparing the yearly performance of all stocks, STTK is a bad performer in the overall market: 87.58% of all stocks are doing better.
STTK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to STTK. No worries on liquidiy or solvency for STTK as it has an excellent financial health rating, but there are worries on the profitability.
STTK Financial Highlights
Over the last trailing twelve months STTK reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS increased by 31.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.61% | ||
| ROE | -77.06% | ||
| Debt/Equity | 0 |
STTK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to STTK. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 27.72% and a revenue growth 494.61% for STTK